Jury selection will begin on September 10, 2007, in the latest round in the HRT litigation involving Wyeth. Pfizer was also a defendant in the case, but, according to Bloomberg, settled with the plaintiffs in late August. This trial involves the claims of three Nevada women, one of whom is terminal, who developed breast cancer after taking the combination hormone replacement therapy drugs Premarin (with Provera) and Prempro.
An earlier case in Reno state court (McCready) was settled just days prior to that trial by Wyeth. The HRT litigation is focused on the failure of Wyeth, Pfizer, and other manufacturers to properly test combination hormone therapy products, over-promotion of the alleged benefits of the therapy, and failure to warn or minimization of risks associated with the drugs including the risk of breast cancer.
The claims of nearly 7,800 women who developed breast cancer after ingesting HRT drugs are pending in state and federal court in the HRT. A number of HRT trials have been completed resulting in several verdicts for the plaintiffs. More trials are expected in the coming months in state courts and in the federal MDL proceedings in Little Rock.
For more information on this subject matter, please refer to the section on Drugs, Medical Devices, and Implants.